Think Research (TSXV:THNK) agreed to acquire closely-held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...
Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...
Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...
BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology, immunology and...
IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) appointed Tommy Kenny as VP intellectual property and legal affairs, general counsel of IntelGenx Corp., the company’s operating subsidiary. Mr. Kenny has been with...
Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...
iBio’s (NYSE American:IBIO) plant-based FastPharming System and customized FastGlycaneering tools were featured in an article in Genetic Engineering & Biotechnology. Sylvain Marcel, Ph.D., VP of protein expression...
Closely-held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...
IntelGenx (TSXV:IGX; OTCQB:IGXT) executed of a definitive supply agreement with Heritage Cannabis Holdings (CSE:CANN; OTCQX:HERTF) to manufacture and supply filmstrip products containing 10 mg of cannabidiol (CBD) using...
Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.